Discover more from PharmaFiles by Aussie17
Twitter Censorship Redux
Twitter's recent actions have raised concerns about censorship once again. Despite giving Elon Musk the benefit of the doubt for a while now, my engagement and views on Twitter have consistently declined over the past three months. Moreover, it's becoming increasingly evident that accounts discussing "controversial" topics, ranging from medical issues to the World Economic Forum and climate change, are also facing similar repercussions.
I'm not alone in observing these trends; many others have reported experiencing the same effects.
Last month, they initiated account suspensions. Fortunately, after a public outcry, most of these accounts were reinstated. However, regrettably, a few smaller accounts have not been reinstated, and they are anxiously hoping that their absence goes unnoticed.
Furthermore, certain articles, like the one below, cannot be retweeted due to their critical stance on the "All in One Vaccine." (Also, please take a moment to check out my friend Dr. Matthew's new Substack.)
The most glaring instance of censorship that I've experienced was when my account mysteriously "unfollowed" Chief Nerd's account. I've been a dedicated follower of Chief for quite some time, but a few days ago, I noticed that I was no longer following him. I am absolutely certain that I did not intentionally "unfollow" him. There's no reason for me to do so; we have always had a cordial relationship, and I greatly appreciate his content. This appears to be a deliberate attempt on Twitter’s part to disrupt connections intentionally.
The good news is that it's reinvigorating my determination to generate more content on Substack. Initially, I began this Substack as a means to archive my pharma revelations, and it seems that this decision was a wise one after all!
Looking ahead, I'm committed to producing and sharing even more general content on Substack!
Signing off for now.
PharmaFiles by Aussie17 is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.